Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma

American Journal of Pathology

Volumn 182, Issue 4, 2013, Pages 1151-1162

  Sharma, Arati ^a   Madhunapantula, Subbarao V ^a   Gowda, Raghavendra ^a   Berg, Arthur ^a   Neves, Rogerio I ^a   Robertson, Gavin P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AURORA B KINASE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE; SMALL INTERFERING RNA; TOZASERTIB; UNCLASSIFIED DRUG; VEMURAFENIB; WEE1 LIKE PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SIZE; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCREENING TEST; TUMOR XENOGRAFT; VALIDATION PROCESS; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; FLOW CYTOMETRY; G2 PHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, NUDE; MITOSIS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84875148077     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.12.019     Document Type: Article

References (52)

1. S.N. Markovic, L.A. Erickson, R.D. Rao, R.H. Weenig, B.A. Pockaj, A. Bardia, C.M. Vachon, S.E. Schild, R.R. McWilliams, J.L. Hand, S.D. Laman, L.A. Kottschade, W.J. Maples, M.R. Pittelkow, J.S. Pulido, J.D. Cameron, and E.T. Creagan Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis Mayo Clin Proc 82 2007 364 380
2. M.P. Purdue, L.E. Freeman, W.F. Anderson, and M.A. Tucker Recent trends in incidence of cutaneous melanoma among US Caucasian young adults J Invest Dermatol 128 2008 2905 2908
3. Y. Chudnovsky, P.A. Khavari, and A.E. Adams Melanoma genetics and the development of rational therapeutics J Clin Invest 115 2005 813 824
4. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
5. M. Libra, G. Malaponte, P.M. Navolanic, P. Gangemi, V. Bevelacqua, L. Proietti, B. Bruni, F. Stivala, M.C. Mazzarino, S. Travali, and J.A. McCubrey Analysis of BRAF mutation in primary and metastatic melanoma Cell Cycle 4 2005 1382 1384
6. J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, H. Kutzner, K.H. Cho, S. Aiba, E.B. Brocker, P.E. LeBoit, D. Pinkel, and B.C. Bastian Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147
7. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
8. C. Dahl, and P. Guldberg The genome and epigenome of malignant melanoma Apmis 115 2007 1161 1176
9. A. Sharma, M.A. Tran, S. Liang, A.K. Sharma, S. Amin, C.D. Smith, C. Dong, and G.P. Robertson Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases Cancer Res 66 2006 8200 8209
10. A. Sharma, N.R. Trivedi, M.A. Zimmerman, D.A. Tuveson, C.D. Smith, and G.P. Robertson Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors Cancer Res 65 2005 2412 2421
11. S.V. Madhunapantula, and G.P. Robertson Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 68 2008 5 8
12. K.S. Smalley PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma Curr Opin Investig Drugs 11 2010 699 706
13. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, and P.B. Chapman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
14. J.C. Rubinstein, M. Sznol, A.C. Pavlick, S. Ariyan, E. Cheng, A. Bacchiocchi, H.M. Kluger, D. Narayan, and R. Halaban Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 J Transl Med 8 2010 67
15. H. Yang, B. Higgins, K. Kolinsky, K. Packman, Z. Go, R. Iyer, S. Kolis, S. Zhao, R. Lee, J.F. Grippo, K. Schostack, M.E. Simcox, D. Heimbrook, G. Bollag, and F. Su RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 2010 5518 5527
16. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, and H. Cho Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
17. D. Solit, and C.L. Sawyers Drug discovery: how melanomas bypass new therapy Nature 468 2010 902 903
18. S.M. Lens, E.E. Voest, and R.H. Medema Shared and separate functions of polo-like kinases and aurora kinases in cancer Nat Rev Cancer 10 2010 825 841
19. X. Wang, S.J. Moschos, and D. Becker Functional analysis and molecular targeting of aurora kinases A and B in advanced melanoma Genes Cancer 1 2010 952 963
20. A. Stathis, and A. Oza Targeting Wee1-like protein kinase to treat cancer Drug News Perspect 23 2010 425 429
21. O. Hashimoto, M. Shinkawa, T. Torimura, T. Nakamura, K. Selvendiran, M. Sakamoto, H. Koga, T. Ueno, and M. Sata Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line BMC Cancer 6 2006 292
22. O. Kaidanovich-Beilin, and J.R. Woodgett GSK-3: functional insights from cell biology and animal models Front Mol Neurosci 4 2011 40
23. R. Zhao, F. Gao, and I.D. Goldman Molecular cloning of human thiamin pyrophosphokinase Biochim Biophys Acta 1517 2001 320 322
24. N. Nguyen, A. Sharma, A.K. Sharma, D. Desai, S.J. Huh, S. Amin, C. Meyers, and G.P. Robertson Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4 Cancer Prev Res (Phila) 4 2011 248 258
25. R.Y. Quong, S.T. Bickford, Y.L. Ing, B. Terman, M. Herlyn, and N.J. Lassam Protein kinases in normal and transformed melanocytes Melanoma Res 4 1994 313 319
26. S.V. Madhunapantula, A. Sharma, and G.P. Robertson PRAS40 deregulates apoptosis in malignant melanoma Cancer Res 67 2007 3626 3636
27. A. Sharma, A.K. Sharma, S.V. Madhunapantula, D. Desai, S.J. Huh, P. Mosca, S. Amin, and G.P. Robertson Targeting Akt3 signaling in malignant melanoma using isoselenocyanates Clin Cancer Res 15 2009 1674 1685
28. E.A. Musgrove, C.E. Caldon, J. Barraclough, A. Stone, and R.L. Sutherland Cyclin D as a therapeutic target in cancer Nat Rev Cancer 11 2011 558 572
29. P. Cohen, and S. Frame The renaissance of GSK3 Nat Rev Mol Cell Biol 2 2001 769 776
30. R. Gowda, S.V. Madhunapantula, D. Desai, S. Amin, and G.P. Robertson Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma Mol Cancer Ther 12 2013 3 15
31. S.J. Huh, C.Y. Chung, A. Sharma, and G.P. Robertson Macrophage inhibitory cytokine-1 regulates melanoma vascular development Am J Pathol 176 2010 2948 2957
32. J.M. Stahl, A. Sharma, M. Cheung, M. Zimmerman, J.Q. Cheng, M.W. Bosenberg, M. Kester, L. Sandirasegarane, and G.P. Robertson Deregulated Akt3 activity promotes development of malignant melanoma Cancer Res 64 2004 7002 7010
33. M. Carmena, and W.C. Earnshaw The cellular geography of aurora kinases Nat Rev Mol Cell Biol 4 2003 842 854
34. R.R. Adams, M. Carmena, and W.C. Earnshaw Chromosomal passengers and the (aurora) ABCs of mitosis Trends Cell Biol 11 2001 49 54
35. D.R. Kellogg Wee1-dependent mechanisms required for coordination of cell growth and cell division J Cell Sci 116 2003 4883 4890
36. C.J. Sherr Cancer cell cycles Science 274 1996 1672 1677
37. N. Keen, and S. Taylor Aurora-kinase inhibitors as anticancer agents Nat Rev Cancer 4 2004 927 936
38. N. Matthews, C. Visintin, B. Hartzoulakis, A. Jarvis, and D.L. Selwood Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev Anticancer Ther 6 2006 109 120
39. E.A. Harrington, D. Bebbington, J. Moore, R.K. Rasmussen, A.O. Ajose-Adeogun, T. Nakayama, J.A. Graham, C. Demur, T. Hercend, A. Diu-Hercend, M. Su, J.M. Golec, and K.M. Miller VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat Med 10 2004 262 267
40. N. Keen, and S. Taylor Mitotic drivers: inhibitors of the Aurora B kinase Cancer Metastasis Rev 28 2009 185 195
41. A. Ribas, and K.T. Flaherty BRAF targeted therapy changes the treatment paradigm in melanoma Nat Rev Clin Oncol 8 2011 426 433
42. F.M. Kaplan, Y. Shao, M.M. Mayberry, and A.E. Aplin Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells Oncogene 30 2011 366 371
43. G.I. Magnussen, R. Holm, E. Emilsen, A.K. Rosnes, A. Slipicevic, and V.A. Florenes High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy PLoS One 7 2012 e38254
44. E. Iorns, C.J. Lord, A. Grigoriadis, S. McDonald, K. Fenwick, A. Mackay, C.A. Mein, R. Natrajan, K. Savage, N. Tamber, J.S. Reis-Filho, N.C. Turner, and A. Ashworth Integrated functional, gene expression and genomic analysis for the identification of cancer targets PLoS One 4 2009 e5120
45. S.E. Mir, P.C. De Witt Hamer, P.M. Krawczyk, L. Balaj, A. Claes, J.M. Niers, A.A. Van Tilborg, A.H. Zwinderman, D. Geerts, G.J. Kaspers, W. Peter Vandertop, J. Cloos, B.A. Tannous, P. Wesseling, J.A. Aten, D.P. Noske, C.J. Van Noorden, and T. Wurdinger In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma Cancer Cell 18 2010 244 257
46. A.A. Dar, L.W. Goff, S. Majid, J. Berlin, and W. El-Rifai Aurora kinase inhibitors: rising stars in cancer therapeutics? Mol Cancer Ther 9 2010 268 278
47. M. Carmena, S. Ruchaud, and W.C. Earnshaw Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins Curr Opin Cell Biol 21 2009 796 805
48. Y. Wang, J. Li, R.N. Booher, A. Kraker, T. Lawrence, W.R. Leopold, and Y. Sun Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator Cancer Res 61 2001 8211 8217
49. K.D. Davies, P.L. Cable, J.E. Garrus, F.X. Sullivan, I. von Carlowitz, Y.L. Huerou, E. Wallace, R.D. Woessner, and S. Gross Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation Cancer Biol Ther 12 2011 788 796
50. M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M.J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16 2005 1723 1739
51. K.J. Niermann, L. Moretti, N.J. Giacalone, Y. Sun, S.M. Schleicher, P. Kopsombut, L.R. Mitchell, K.W. Kim, and B. Lu Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition Radiat Res 175 2011 444 451
52. P.C. De Witt Hamer, S.E. Mir, D. Noske, C.J. Van Noorden, and T. Wurdinger WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe Clin Cancer Res 17 2011 4200 4207